A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

10.1016/j.jtocrr.2022.100416

Saved in:

Bibliographic Details
Main Authors:	Lai, Gillianne GY, Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob JS, Sim, Ngak Leng, Tan, Aaron C, Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie PL, Rohatgi, Neha, Yeong, Joe PS, Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders MJ, Tan, Eng-Huat, Tan, Daniel SW
Other Authors:	DEPARTMENT OF COMPUTER SCIENCE
Format:	Article
Language:	English
Published:	ELSEVIER 2024
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System Lung cancer Epidermal growth factor receptor Immunotherapy Biomarkers CELL LUNG-CANCER TUMOR MUTATIONAL BURDEN OPEN-LABEL PLUS IPILIMUMAB IMMUNE ESCAPE DOCETAXEL PD-L1 PEMBROLIZUMAB BLOCKADE ASSOCIATION
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/248899
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1016/j.jtocrr.2022.100416